With the current administratioin, some federal activities like PAC CARB (experts for antibiotic resistance) and USPSTF (for prevention) seemed to come to a halt. But others, like MEDPAC (advisory body on Medicare) percolate right along.
Why is this?
###
Chat GPT answers.
###
Yes. What you are noticing is real, and the explanation is mostly where each body sits constitutionally and administratively.
| Body | What it really is | Who controls its machinery | Result under Trump II |
|---|---|---|---|
| MedPAC | Independent legislative-branch agency advising Congress | Congress/GAO; commissioners appointed by Comptroller General | Keeps operating |
| USPSTF | Statutory expert panel supported by AHRQ/HHS | HHS ultimately controls appointments, support, meetings | Essentially stalled |
| PACCARB | Federal advisory council advising HHS Secretary | HHS; charter derives from presidential/HHS authority | Long hiatus; now restarting |
MedPAC is the odd one out
MedPAC isn't really an “HHS advisory committee” at all. Congress created it in 1997 as an independent congressional agency. Its 17 commissioners serve staggered three-year terms and are appointed by the Comptroller General (GAO), not by the President or HHS Secretary. (MedPAC)
Even more important, it has statutory work products and deadlines. By law it reports to Congress each March on Medicare payment policy, plus its June report on broader Medicare issues. It produced both reports normally in 2026 and has continued its regular public meeting cycle. (MedPAC)
So an HHS Secretary cannot simply say, “Don't hold the MedPAC meeting.” MedPAC doesn't work for him.
USPSTF sounds independent—but isn't institutionally independent in the same way
The statute famously says the Task Force should be “independent” and, to the extent practicable, insulated from political pressure. But organizationally its members are appointed through AHRQ and its entire operating apparatus depends on AHRQ/HHS. (USPSTF)
And the Supreme Court's June 2025 Kennedy v. Braidwood decision made the hierarchy unusually explicit: USPSTF members are inferior federal officers because the HHS Secretary can remove them and review/block their recommendations. (KFF)
That means “scientifically independent” ≠ independent of the executive branch.
And indeed, USPSTF has effectively ground to a halt: it last met in March 2025, and by July 2026 HHS had canceled/postponed its fourth consecutive scheduled meeting. (Reuters)
PACCARB is even more obviously executive-branch dependent
PACCARB advises the HHS Secretary and operates as a federal advisory council; its charter traces back to presidential executive authority, with renewal authority delegated to HHS. (Health.gov)
Its January 2025 meeting was canceled during the transition and it remained dormant until June 16, 2026. So your recollection is correct, with one important update: PACCARB has now come back to life. It met in June to work on the 2026–2031 CARB National Action Plan and has a full meeting scheduled for September 9–10, 2026. (Health.gov)
So I would characterize the phenomenon this way:
MedPAC has structural independence; USPSTF has scientific independence but executive-branch dependence; PACCARB is fundamentally an executive-branch advisory body.
That distinction turns out to be enormously consequential. An administration that wants to slow an HHS advisory apparatus often needs little more than no meeting, no appointments, no Federal Register notice, no staff support. Stopping MedPAC would require confronting a separate congressional institution with explicit statutory duties.
There is also a nice irony here: MedPAC may actually be one of the most durable federal health-policy intellectual institutions precisely because Congress designed it as a boring, technocratic legislative agency rather than as an HHS advisory committee.
###
- Chat GPT offered to set up a recurrent function to monitor for signs of activity each week at PAC CARB and USPSTF.
###
Could an expert have accurately predicted this sequence (MEDPAC, PAC CARB, USPSTF) ahead of the events - say, predictions in Feb 2025?
###Yes — with an important qualification. By about February 20–25, 2025, a very good federal-health-policy analyst could plausibly have predicted the pattern we subsequently saw. The exact duration of the shutdowns would have been much harder.
A reasonable “forecast written February 21, 2025” could have looked like this:
| Institution | Feb. 2025 forecast | Confidence |
|---|---|---|
| MedPAC | Will continue essentially normally | 95% |
| PACCARB | Likely prolonged suspension/uncertain future | 80–90% |
| USPSTF | Significant HHS interference or meeting disruption likely | 60–75% |
| USPSTF specifically frozen for >1 year | Possible, but not obvious | 30–40% |
MedPAC was the easy prediction
An expert who understood the organizational chart should have been almost certain about MedPAC. It is an independent congressional agency, with commissioners appointed by the Comptroller General, career staff, and congressionally mandated March/June reports. (MedPAC)
Trump and Kennedy simply weren't sitting above it in the chain of command. Moreover, MedPAC had already held its January 16–17 meeting, with its March 6–7 meeting scheduled, and it subsequently held that meeting normally. (MedPAC)
So in February 2025:
Prediction: MedPAC keeps chugging along.
That would barely have required political insight; it followed from institutional structure.
PACCARB was already flashing red by January
Here we have to be careful about hindsight. By February it was no longer possible to “predict” PACCARB's initial disruption: its January 28–29 meeting had already been canceled on January 23 because the new administration was reviewing federal policy and communications. (AMR Solutions)
But an expert could certainly have predicted that the pause might become prolonged rather than being an ordinary transition-week delay. The broader HHS communications freeze had already canceled outside meetings and other activities across CDC, NIH and FDA. (Reuters)
Then came a much stronger signal on February 19. Trump's Executive Order 14217 explicitly ordered HHS to terminate the Long COVID advisory committee and CMS's Health Equity Advisory Committee, and directed White House officials to identify additional Federal Advisory Committees for termination. (The White House)
At that point, betting that an HHS-dependent Presidential Advisory Council such as PACCARB would have trouble getting back on its feet was quite reasonable.
USPSTF is the really interesting prediction
This one looks much more prescient.
On the surface in February 2025, USPSTF still looked healthier than PACCARB. AHRQ was accepting nominations for new USPSTF members through March 15, 2025, and the Task Force continued publishing draft plans and recommendations into March and April. (USPSTF)
So “USPSTF will stop functioning” was not obvious.
But a lawyer or health-policy expert following Braidwood had an extraordinary clue. As early as January 14, contemporary legal analysis pointed out that even the Fifth Circuit accepted that the HHS Secretary could remove USPSTF members at will. (Vox)
And on February 20–21, 2025, the Trump administration itself made the signal considerably stronger. Its Supreme Court position defended the ACA preventive-services structure precisely on the ground that the HHS Secretary exercises ultimate supervision over USPSTF. Contemporary reporting explicitly noted that this could allow Secretary Kennedy to remove members, prevent recommendations from becoming binding, or steer what the Task Force examined. (AJMC)
Meanwhile, HHS had just postponed ACIP's February meeting, and within days FDA's vaccine-advisory meeting was canceled. (AP News)
Put those pieces together and a sophisticated February 2025 forecast could reasonably have said:
“Don't confuse USPSTF's statutory/scientific independence with operational independence. It relies on AHRQ/HHS, Kennedy has supervisory and removal authority, and this administration is already suspending advisory committees. USPSTF is therefore at substantial risk even though it may continue functioning for several months.”
And that is impressively close to what happened.
So I would score the hypothetical expert this way
MedPAC surviving: highly predictable.
PACCARB going dormant: predictable—but by February the first cancellation had already happened.
USPSTF eventually being crippled: genuinely foreseeable by late February 2025, although predicting the extraordinary length of the paralysis would have been a bolder call.
The deeper predictive variable wasn't really Trump vs. science or even Republican vs. Democrat. It was:
Where does the institution sit in the federal organizational tree, who appoints/removes its members, who supplies its staff and money, and can HHS simply decline to convene it?
On that model, the sequence MedPAC → PACCARB → USPSTF makes considerable sense ex ante, not merely in hindsight.
###
Same prediction, but it's December 2024, not Feb 2025.
###
You're right. December 2024 is the clean test, because none of the Trump-II disruptions had yet occurred. Looking strictly at what an expert knew then, I would dial back my earlier claim.
An unusually perceptive expert could have predicted the ordering of vulnerability, but predicting the actual degree of paralysis would have been impressive rather than obvious.
If I had been asked on December 20, 2024, I think a defensible forecast would have been:
| Body | December 2024 prediction | My ex-ante confidence |
|---|---|---|
| MedPAC | Trump transition should have little operational effect | 95% |
| PACCARB | More vulnerable to disruption/reconstitution under new HHS | 40–60% |
| USPSTF | Some political/legal intervention possible, but probably continues | 25–40% |
| Both PACCARB and USPSTF substantially paralyzed | Possible, but aggressive prediction | ~20–30% |
Those percentages are judgment calls, not measured probabilities.
MedPAC really was predictable
This part was easy before Trump took office. MedPAC was already an independent congressional agency, not an HHS body. Its commissioners were appointed through GAO/Comptroller General, it had statutory reporting obligations to Congress, and it was proceeding with its normal work cycle; it held its December 12–13, 2024 meeting normally.
A knowledgeable observer could therefore have said in December:
“Whatever happens to executive-branch health advisory committees, MedPAC should basically carry on.”
That prediction deserves little clairvoyance.
PACCARB: structurally vulnerable—but there were actually reassuring signals
Here is where hindsight matters.
PACCARB was unmistakably an HHS-dependent Presidential advisory council. It advised the HHS Secretary and operated under FACA. Thus a change of administration presented considerably more risk than for MedPAC.
But look at what someone actually saw in December 2024:
- HHS had renewed PACCARB's charter only months earlier, with the renewal published October 3.
- On November 29, 2024, HHS formally announced its next public meeting for January 28–29, 2025, including hotel, webcast, registration and public-comment arrangements.
So predicting in December that the January meeting itself would be summarily canceled and PACCARB would then disappear for more than a year would have been a pretty sharp call.
What an expert reasonably could have said was:
“PACCARB is much less protected than MedPAC. It's a presidential/HHS advisory mechanism, so I would watch it closely during the transition.”
That's different from confidently forecasting what actually happened.
USPSTF is even more interesting
In December 2024, USPSTF did not look like an organization about to grind to a halt.
It was actively issuing recommendations in December, and on December 19, 2024, AHRQ opened its ordinary annual solicitation for nominations of new USPSTF members.
Moreover, Congress had specifically authorized AHRQ to provide the Task Force with scientific, technical and administrative support.
There was, however, one very sophisticated warning sign: Braidwood.
The Fifth Circuit's June 2024 opinion had already said explicitly that the statute did not prevent the HHS Secretary from removing USPSTF members at will. The Supreme Court petition was pending by September 2024.
Thus a health-law expert could have noticed something quite subtle:
USPSTF's celebrated “independence” did not necessarily protect it administratively from an HHS Secretary hostile to its operation.
And by December, RFK Jr. had already been named Trump's intended HHS Secretary on November 14, 2024, producing widespread expectations of substantial changes in federal public-health policy.
Still, Kennedy's most conspicuous pre-inauguration targets were vaccines, pharmaceuticals, food and chronic disease—not a publicly announced plan to immobilize USPSTF. So predicting the Task Force won't meet for more than a year would have gone substantially beyond the evidence then available.
Therefore, my answer changes
If somebody showed me a dated December 2024 memo saying:
MedPAC: essentially unaffected.
PACCARB: high risk of meeting cancellations/inactivity.
USPSTF: likely eventually disrupted because its independence is less institutionally secure than it looks.
…I would now say that person understood the federal machinery unusually well.
If the memo went further and predicted:
PACCARB's January meeting will be canceled immediately after inauguration, it will remain dormant into 2026, and USPSTF will subsequently cease its normal meeting cycle as well,
I'd call that genuinely prescient, not something any competent Washington health-policy expert should automatically have foreseen.
And there's a rather elegant December-2024 ranking an expert could have derived purely from institutional architecture:
MedPAC = legislative-branch insulation → PACCARB = direct presidential/HHS dependence → USPSTF = statutory/scientific independence but hidden executive dependence.
The events of 2025–26 almost became an inadvertent natural experiment testing those three different forms of “independence.” That, I think, is the really interesting story.
